Clinical Pharmacology and Therapeutics
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update
Craig R. Lee
1
,
Jasmine A Luzum
2
,
Katrin Sangkuhl
3
,
Roseann S. Gammal
4, 5
,
Marc S. Sabatine
6
,
Charles Michael Stein
7
,
David F. Kisor
8
,
Nita A. Limdi
9
,
Yee Ming Lee
10
,
Stuart A. Scott
11, 12
,
Jean-Sébastien Hulot
13
,
Dan M. Roden
14
,
Andrea Gaedigk
15
,
Kelly E. Caudle
5
,
Teri E. Klein
3
,
Julie A. Johnson
16
,
Alan R. Shuldiner
17
2
4
Department of Pharmacy Practice Massachusetts College of Pharmacy and Health Sciences Boston Massachusetts USA
|
8
Department of Pharmaceutical Sciences Manchester University Fort Wayne Indiana USA
|
13
Publication type: Journal Article
Publication date: 2022-02-08
scimago Q1
SJR: 1.988
CiteScore: 12.7
Impact factor: 6.3
ISSN: 00099236, 15326535
DOI:
10.1002/cpt.2526
Pharmacology
Pharmacology (medical)
Abstract
CYP2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 genotype impacts clopidogrel active metabolite formation. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. This guideline is an update to the 2013 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of clopidogrel based on CYP2C19 genotype and includes expanded indications for CYP2C19 genotype-guided antiplatelet therapy, increased strength of recommendation for CYP2C19 intermediate metabolizers, updated CYP2C19 genotype to phenotype translation, and evidence from an expanded literature review (updates at www.cpicpgx.org).
Found
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.